Erscheinungsdatum: 05/2011, Medium: Buch, Einband: Gebunden, Titel: Tumor-Associated Fibroblasts and their Matrix, Auflage: Edition, Redaktion: Mueller, Margareta M. // Fusenig, Norbert, Verlag: Springer-Verlag GmbH // Springer Netherland, Sprache: Englisch, Schlagworte: Biomedizin // Medizin // Krebs // Krankheit // Tumor // Onkologie // Radioonkologie // Forschung // medizinisch // psychologisch // Heilkunde // Humanmedizin // Vorklinische Medizin // Grundlagenwissenschaften, Rubrik: Allgemeinmedizin // Diagnostik, Therapie, Seiten: 452, Herkunft: NIEDERLANDE (NL), Reihe: The Tumor Microenvironment (Nr. 4), Informationen: Book, Gewicht: 817 gr, Verkäufer: averdo
Erscheinungsdatum: 27.11.2013, Medium: Taschenbuch, Einband: Kartoniert / Broschiert, Titel: Tumor-Associated Fibroblasts and their Matrix, Auflage: 2011, Redaktion: Fusenig, Norbert E. // Mueller, Margareta M., Verlag: Springer Netherlands // Springer Netherland, Sprache: Englisch, Schlagworte: Onkologie, Rubrik: Allgemeinmedizin // Diagnostik, Therapie, Seiten: 472, Informationen: Paperback, Gewicht: 709 gr, Verkäufer: averdo
The first comprehensive and most recent overview of the topic, this ready reference and handbook reviews current knowledge of TAAs, their subclasses, and pinpoints their application areas in medicine. In addition, it emphasizes target identification procedures, the need for an accurate and thorough analysis of the function of TAAs, and the validation of those in clinical settings. The whole is rounded off with an overview of currently approved therapeutic antibodies. The result is a must-have for biologists and oncologists in science, clinics and industry.
Analysis of multidirectional immunological responses at the tumor site allows forming a new concept of The Tumor Immunoenvironment, which is introduced and discussed in the present book with a particular focus on the role of immune cells in controlling the tumor microenvironment at different stages of cancer development. The main goal of this publication is to provide an overview of the current knowledge on the complex and unique role of the immune system, tumor-associated inflammation and tumor-mediated immunomodulation in cancer progression in a way that allows understanding the logistics of cellular and molecular interactions in the tumor lesions.
The growing knowledge on tumor-immune response interactions and on the tumor microenvironment did not translate so far into better control of cancer by anti-tumor vaccination. The percentage of patients who benefited from vaccination strategies is still too small to justify their general use. It is the aim of this book to present an alternative to the conventional approach of developing injected tumor vaccines to activate anti-tumor immunity, which will fight cancer. It is argued that in situ tumor ablation (destruction) that involves tumor antigen release; cross presentation and the release of danger associated molecular patterns (DAMPs) can make the tumor its own cellular vaccine. Tumor ablation methods using chemicals, radiation, photodynamic therapy, cryoablation, high-temperature, radiofrequency, high intensity focused ultrasound, and electric-based ablation have been developed for focal tumors. In this book experts will deal with two main topics: I. What are the principles of the various ablation modalities, and II. How each method affects the tumor cells and their microenvironment, and how these effects are responsible for the induction of specific anti-tumor immunity. The aims of this book are thus: 1. Familiarize the readers with various methods of in situ tumor ablation. 2. Review the literature and stimulate comparisons on the efficacy of different ablation methods for the treatment of tumors of different histotypes. 3. Review the literature on the effects of various ablation methods on systemic and local anti tumor immunity and on other manifestations of the interactions of tumors with their microenvironment. 4. Stimulate comparative studies on the immunostimulatory effects of different ablation modalities.
The fact that tumors are composed of both tumor cells and host cells has long been known. These tumor-associated cells include vascular endothelial cells and pe- cytes, as well as inflammatory cells such as neutrophils, monocytes, macrophages, mast cells and eosinophils, and lymphocytes. The tumor cells also interact with stromal cells and with elements of the tissue extracellular matrix. What has been less appreciated is the role that these cells could have in modulating the growth, invasion, and metastasis of the tumor. Early on, the elements of what we now call the tumor microenvironment were considered to be more or less innocent bysta- ers to the role of the tumor cells as they grew and invaded local sites. Today, there is an increased understanding of the critical role of the tumor microenvironment as dramatically influencing the course of tumor development and dissemination. This volume represents a superb compilation of the latest thoughts and data regarding the role of each essential component of the tumor microenvironment in cancer development and progression. Perhaps, the earliest recognition of the role of nonmalignant cells as cancer re- lators was the recognition that lymphocytes can participate in what was termed 'immune surveillance' in the 1960s. Our understanding of tumor immunity has improved markedly since then, and there are now successful clinical studies sh- ing the potential use of immune-based therapies in cancer treatment.
There is now a pressing need to discuss the already described and newly emerging mechanisms to see how they can be put together in more or less cohesive structure and how they can help to improve immune response to tumors. This monograph will, for the first time, present a comprehensive overview of different mechanisms of immune dysfunction in cancer as well as therapeutic approaches to their correction. It will discuss a number of new mechanisms that have never been discussed in a monograph before: T-cell inhibitory molecules, regulatory tolerogenic DCs, and signaling pathways in antigen-presenting cells involved in T-cell tolerance. TOC:Introduction.- Mechanisms and Therapeutic Reversal of the Defects in T-Cell Function in Cancer.- Molecular Mechanisms of Tumor-Associated T-Cell Tolerance.- T-Cell Tolerance.- T-Cell Inhibitory Molecules and Suppression of T-Cell Function In Cancer.- CTLA-4 and T-Cell Tolerance in Cancer.- Regulatory T-Cells in Cancer.- T-Cell Apoptosis in Cancer.- Defects in Dendritic Cell Differentiation in Cancer and Tumor Escape.- Dendritic Cells With Tolerogenic Potential in Cancer.- Signaling Pathways in Antigen-Presenting Cells Involved in Induction of T-Cell Tolerance.- Macrophages and Tumor Development.- Immature Myeloid Suppressor Cells in Tumor-Induced T-Cell Tolerance.- Arginin Metabolism as A Critical Element of Tumor Suppression in Cancer.- Role of Reactive Oxygen Species in T-Cell Defects in Cancer.- Cytokine Production in Cancer and their Negative Effect on Immune Response.- Inflammation and Immune Abnormalities in Cancer.- Tumor Stroma and Antitumor Immune Response.- Tumor Associated Immune Defects. Where are Now and Where are We Going.
Interaction between malignant cells and their surrounding tissue plays a crucial role in tumor growth, invasiveness and spreading to the distant organs. New findings provide evidence of a principal importance of the immune cells for controlling this interaction and orchestrating multiple events in the tumor microenvironment. The balance between immune cells that support tumor progression and immune cells that sustain tumor-controlling immune surveillance is tightly regulated by various factors originated from both the malignant and non-cancerous cells in the tumor microenvironment. Analysis of multidirectional immunological responses at the tumor site allows forming a new concept of The Tumor ImmunoEnvironment, which is introduced and discussed in the present book with a particular focus on the role of immune cells in controlling the tumor microenvironment at different stages of cancer development. The main goal of this publication is to provide an overview of the current knowledge on the complex and unique role of the immune system, tumor-associated inflammation and tumor-mediated immunomodulation in cancer progression in a way that allows understanding the logistics of cellular and molecular interactions in the tumor lesions. Moreover, it is discussed how these interactions evolve during cancer progression and in response to different kinds of anticancer therapy. It is anticipated that the book will attract many researchers and clinicians in the field of basic and applied tumor immunobiology and open new opportunities for collaborative programs aiming at the development of effective and feasible therapeutic approaches to cancer treatment.
Gliomas, which comprise astrocytic, oligodendroglial, and ependymal lesions, are the most frequent primary intracranial tumors. This volume summarizes the enormous advances in our knowledge of gliomas that have occurred during recent years. The first part of the book focuses on the glial tumor entities, with detailed discussion of diagnosis, molecular genetics, and tumor origin. This section also contains a chapter on hereditary tumor syndromes associated with gliomas and the molecular mechanisms underlying these specific diseases. The second part is devoted to the clinical management of gliomas and provides insights into novel developments regarding neuroimaging, surgical management, radiation therapy, adjuvant therapy, experimental approaches, and the neurotoxicity of treatment. The final part of the book addresses angiogenesis and epigenetic regulation of gene expression in gliomas.